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OBJECTIVE—FTO is the most important polygene identiﬁed for
obesity. We aimed to investigate whether a variant in FTO affects
type 2 diabetes risk entirely through its effect on BMI and how
FTO inﬂuences BMI across adult life span.
RESEARCH DESIGN AND METHODS—Through regression
models, we assessed the relationship between the FTO single
nucleotide polymorphisms rs9939609, type 2 diabetes, and BMI
across life span in subjects from the Norwegian population-based
HUNT study using cross-sectional and longitudinal perspectives.
For replication and meta-analysis, we used data from the Malmö
Diet and Cancer (MDC) and Malmö Preventive Project (MPP)
cohorts, comprising a total sample of 41,504 Scandinavians.
RESULTS—The meta-analysis revealed a highly signiﬁcant as-
sociation for rs9939609 with both type 2 diabetes (OR 1.13;
P = 4.5 3 1028) and the risk to develop incident type 2 diabetes
(OR 1.16; P = 3.2 3 1028). The associations remained also after
correction for BMI and other anthropometric measures. Further-
more, we conﬁrmed the strong effect on BMI (0.28 kg/m2 per risk
allele; P = 2.0 3 10226), with no heterogeneity between different
age-groups. We found no differences in change of BMI over time
according to rs9939609 risk alleles, neither overall (ΔBMI = 0.0
[20.05, 0.05]) nor in any individual age stratum, indicating no
further weight gain attributable to FTO genotype in adults.
CONCLUSIONS—We have identiﬁed that a variant in FTO alters
type 2 diabetes risk partly independent of its observed effect on
BMI. The additional weight gain as a result of the FTO risk variant
seems to occur before adulthood, and the BMI difference remains
stable thereafter. Diabetes 60:1637–1644, 2011
Genomewide association studies (GWAS) haveidentiﬁed a strong correlation between BMI andFTO single nucleotide polymorphisms (SNPs)(1–4), and the association has been conﬁrmed
in multiple populations (reviewed in 5). The FTO risk var-
iants are also associated with obesity-related traits (6–8).
However, these effects appear to be secondary to weight
increase because the associations are attenuated after
adjusting for BMI (2). In contrast, we and others have
found that the association with type 2 diabetes may not be
completely mediated through BMI, because it remains
signiﬁcant after BMI correction (9). This indicates that the
relationship between sequence variation in FTO and type 2
diabetes is not fully mediated through BMI or that BMI in
some populations does not reveal accurate estimates of
the effect of FTO on adiposity.
Various studies have investigated the effect of FTO
variants on BMI and weight in a longitudinal perspective
(10–18) but with diverging results. With access to extensive
data from three large Scandinavian populations, through
a meta-analysis approach using both cross-sectional and
longitudinal data, we aimed to investigate whether the FTO
risk allele affects type 2 diabetes risk after correction for
BMI and whether it inﬂuences weight gain during adult life.
RESEARCH DESIGN AND METHODS
Deﬁnition of cohorts. We studied HUNT2, a subset (aged $20) of a Norwe-
gian population-based health survey (Nord-Trøndelag Health Study) (19). Our
material comprised 1,740 diabetic individuals (1,543 with type 2 diabetes) and
3,856 population-based control subjects drawn from the same study pop-
ulation. We also had access to data on diabetes status, weight, and height from
HUNT1 (1985) for 4,625 of the 5,596 subjects in HUNT2 (1995), i.e., 10-year
follow-up. During these 10 years, 1,089 individuals developed type 2 diabetes.
Diagnosis of diabetes was self-reported or identiﬁed by standard tests if ran-
dom glucose was .8.0 mmol/L.
The Malmö Diet and Cancer (MDC) cohort (20) with baseline examinations
from 1991 to 1996 consisted of 28,449 individuals. All men born between 1923
and 1945 and all women born between 1923 and 1950 from Malmö were
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invited. Diabetes diagnosis at baseline was self-reported or diagnosed if fasting
plasma glucose was $7.0 mmol/L.
In the Malmö Preventive Project (MPP) cohort (21), 33,346 subjects from
Malmö participated in a health screening. Men were included from 1974 to
1990, and women were included from 1980 to 1992. Eligible participants
(25,000) were invited to a rescreening visit during 2002–2006. Of those invited,
16,061 nondiabetic subjects, 2,063 of whom developed type 2 diabetes during
follow-up, were included in the current study. Diabetes diagnosis was taken
from patient records or if fasting plasma glucose was $7.0 mmol/L.
The clinical characteristics of individuals from the three cohorts are shown
in Table 1.
SNP selection, genotyping, and quality control. Because the reported
obesity-associated FTO SNPs are in strong to perfect linkage disequilibrium
(LD) (pairwise r2 . 0.8; HapMap; CEU, release 21), we included rs9939609,
reported by the ﬁrst GWAS (2), as proxy. We genotyped HUNT2 subjects by
MassARRAY iPLEX System (SEQUENOM, San Diego, CA). Duplicate con-
cordance rate was 99.7% (N = 3,761). MDC individuals were genotyped using
MassARRAY iPLEX System or a TaqMan assay (Applied Biosystems, Foster
City, CA). Individuals (249 total) were genotyped with both methods (99.4%
allelic concordance rate). A total of 8,175 individuals were genotyped twice
(allelic concordance rate 99.3%). MPP subjects were genotyped by TaqMan
assay with duplicate concordance rate 99.7% (N = 7,926). The ﬁnal genotyping
success rates were 99.7, 99.2, and 97.2%, in HUNT2, MPP, and MDC, re-
spectively. The FTO SNP was in Hardy-Weinberg equilibrium (P value .0.05)
in all cohorts.
Statistical analysis.We used logistic regression to investigate the association
between type 2 diabetes and FTO genotype under an additive model. Age, sex,
different combinations of BMI, waist circumference, and waist-to-hip ratio
were included as covariates. In HUNT2 and MPP, follow-up measures were
used unless otherwise stated. In MDC, baseline measures were used because
of no available follow-up. To evaluate the risk of developing incident type 2
diabetes according to the three FTO genotypic classes, we designed a case-
control study using only subjects who were healthy at baseline. Those de-
veloping type 2 diabetes during follow-up were deﬁned as cases and the rest as
control subjects. We used logistic regression models corrected for sex, base-
line age, and BMI. In a second step, we included the change in BMI over time
(ΔBMI) as an additional cofactor.
To analyze the association between FTO genotype and BMI, we used linear
regression models assuming additive effects of allele dosage with adjustment
for age, sex, and diabetes status. Logarithmic transformation of BMI values did
not change the results; thus, only results using nontransformed BMI are pre-
sented. To assess whether the allele-wise increase in BMI differed across
different adult ages, we performed individual analysis in every 10-year age
stratum in the cross-sectional and longitudinal datasets. Finally, meta-analysis
was performed to combine the regression coefﬁcients (per allele change in
BMI) with their standard errors from within the three cohorts and for each
speciﬁc age-group. Interstudy heterogeneity and heterogeneity between different
age-groups were estimated using Cochran’s Q test and the I2 statistic. Overall
estimates were calculated using a ﬁxed-effect model with inverse variance.
We performed statistical analyses by PLINK (22) and Stata SE v10.0 (Stata,
Brownsville, TX) or SPSS (version 18; SPSS Inc., Chicago, IL). Meta-analysis
statistics and plots were produced using the METAN module (23) developed for
Stata and with GWAMA (Genome-Wide Association Meta-Analysis) software (24).
RESULTS
Relationship among FTO, type 2 diabetes, and obesity-
related quantitative traits across life span in HUNT.
After correction for age and sex, we observed a strong as-
sociation with type 2 diabetes for rs9939609 in HUNT2. This
association remained signiﬁcant after correction for BMI
(OR 1.19 [95%CI 1.09–1.30]; P = 1.8 3 1025). The FTO var-
iant also conferred an increased risk for type 2 diabetes
after adjustment for waist circumference and waist-to-hip
ratio. These results suggested that rs9939609 has an effect
on the risk of type 2 diabetes, an effect that cannot be en-
tirely explained through increased BMI or central obesity.
Using a cross-sectional design, we observed that the FTO-
associated allele-wise increase in BMI persisted at the same
level throughout life (Supplementary Fig. 1). In addition,
rs9939609 3 age interactions on obesity-related traits were
all nonsigniﬁcant (Supplementary Table 1), suggesting that
changes in these traits by age were not dependent on the
individual’s FTO genotype.
Next, we studied longitudinal change in the association
between FTO and BMI during 10-year follow-up from
HUNT1 to HUNT2. The FTO variant showed an association
with all obesity-related quantitative traits (Supplementary
Table 1). There was, however, no association between
rs9939609 and ΔBMI between 1985 and 1995. This sug-
gested that the FTO-associated relative difference of BMI
is established before adulthood and then remains stable.
Conﬁrmation of the ﬁndings from HUNT–meta-analysis
in 41,504 Scandinavians. Clinical characteristics of indi-
viduals from the three different cohorts are presented in
Table 1. The minor allele frequencies of rs9939609 in non-
diabetic individuals were 0.42, 0.41, and 0.41 in HUNT2,
MPP, and MDC, respectively.
The meta-analysis demonstrated that the association
between rs9939609 and type 2 diabetes was strong after
adjustment for age and sex (OR 1.13 [95%CI 1.08–1.19]; P =
4.5 3 1028) and remained signiﬁcant after BMI correction
(OR 1.09 [95%CI 1.04–1.15]; P = 1.2 3 1024; Fig. 1A and B).
Correction for waist-to-hip ratio or waist circumference
instead of BMI did not change the results (Supplementary
Fig. 2A–C). To further elucidate whether rs9939609 exerts
an effect on type 2 diabetes independently of BMI, we
evaluated the risk to develop incident type 2 diabetes
according to FTO genotype during follow-up. As shown in
Supplementary Fig. 3A–C, the association remained simi-
lar for incident type 2 diabetes after correction for sex and
baseline age and BMI (OR 1.12 [95%CI 1.05–1.18]; P = 1.13
1024) and after correction also for ΔBMI (OR 1.11 [95%CI
1.05–1.18]; P = 1.5 3 1024).
The meta-analysis of the FTO-associated allele-wise
effect on BMI using cross-sectional data conﬁrmed the
strong effect of the FTO SNP on BMI (0.28 kg/m2 per risk
allele [P = 2.03 10226]; Fig. 2A). Furthermore, we detected
no heterogeneity in the effect sizes for the FTO risk allele
between the different age-groups (Fig. 2B). Finally, Fig. 3
shows the linear regression summary results between
rs9939609 and ΔBMI for all HUNT and MPP individuals for
whom longitudinal data were available. There was no sig-
niﬁcant difference in ΔBMI according to overall number of
rs9939609 risk alleles (ΔBMI = 0.0 [20.05, 0.05]) or in any
individual age stratum (Fig. 3B). Hence, the FTO-associated
effect on BMI seems to establish relatively early in life, and
the relative BMI difference remains stable across adult
life.
DISCUSSION
To our knowledge, this is the largest study investigating
the effect of FTO sequence variants on type 2 diabetes and
BMI across the whole range of adult ages and in a longi-
tudinal perspective. In 41,504 Scandinavians, we demon-
strate that a common variant of FTO does not mediate type
2 diabetes risk entirely through its inﬂuence on BMI. Al-
though our ﬁndings are comparable with some earlier stud-
ies (25–27), they contrast previous results reported in most
populations studied to date, including Europeans (1–3,8).
Reasons for the diverging results could be differences
in selection or recruitment of cases and control subjects
between studies, differences in undetected key effects at
early age, or population-speciﬁc environmental factors that
may interact with the way FTO works to inﬂuence the risk
of type 2 diabetes. In an attempt to capture the complex
relationship between FTO, BMI, and type 2 diabetes during
the life course, we performed an analysis on incident type 2
diabetes. The results remained similar in the longitudinal
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study both when we controlled for BMI at baseline (before
diabetes was diagnosed), ΔBMI, or waist circumference
and/or waist-to-hip ratio as covariates in the regression
analyses. None of the covariates alone or in combination
with BMI changed our results notably. FTO still conferred
an increased risk for type 2 diabetes.
How sequence variation in FTO could possibly affect
type 2 diabetes risk in other forms than through increased
adiposity remains elusive. No associations have been
reported between FTO SNPs and glucose tolerance or in-
sulin sensitivity. A link between SNPs in FTO and altered
lipid proﬁles has been suggested (6,9), but we could not
conﬁrm this in our meta-analysis (Supplementary Table 2).
It has been suggested that rs9939609 affects the primary
allelic FTO transcript levels (28), and correlations have
been observed in peripheral tissues between BMI of tis-
sue donors and FTO mRNA expression levels (29). It is
noteworthy that three recent FTO expression studies
support a potential role in type 2 diabetes independently of
BMI. One study found no association between FTO ex-
pression and BMI in islet cells (30). Another study reported
an inverse correlation between Fto mRNA and glucose in
mice after correction for body weight (31). Finally, a third
study found an increase of FTO mRNA and protein levels
in muscle from type 2 diabetic patients compared with
healthy lean control subjects or BMI-matched obese non-
diabetic individuals (32). The latter also suggests that
increased FTO expression in type 2 diabetic patients con-
tributes to reduced mitochondria oxidative capacities, lipid
accumulation, and oxidative stress, all associated with type
2 diabetes. It is also possible that the rs9939609 SNP (or a
SNP in strong LD) affects another gene in the region, which
has the potential to alter type 2 diabetes risk independently
of BMI (33).
FIG. 1. Meta-analysis plots of association between FTO and type 2 diabetes comprising 4,317 subjects with type 2 diabetes and 37,187 control
subjects. A: Meta-analysis plot of association between FTO rs9939609 and type 2 diabetes after correction for age and sex (allelic OR 1.13 [95%CI
1.08–1.19]). B: Meta-analysis plot of association between FTO rs9939609 and type 2 diabetes after correction for age, sex, and BMI (allelic OR 1.09
[ 1.04–1.15]). We observed a tendency toward heterogeneity between the samples (P = 0.064), and the variation in the estimate attributable to
heterogeneity was calculated to 63.7%. The ORs for the overall estimates were calculated using a ﬁxed-effect model with inverse variance. The
weighting (%weight) represents the inverse variance of each studies’ effect estimator.
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The association between FTO sequence variants and
BMI is not established at birth (2,34) but seems to evolve
gradually before adulthood (2,35,36). It is not clear how
FTO genotype affects BMI after adolescence and develops
during the life course (10–18), although a recent longitu-
dinal Finnish study suggests that the effect may continue
into adulthood since they found an association between
rs9939609 and BMI at age 31, which could not be explained
by the BMI at age 14 (18). Using cross-sectional and lon-
gitudinal designs, we identiﬁed in the three Scandinavian
populations that the relative difference in mean BMI among
individuals with different rs9939609 genotypes remains
surprisingly stable across all adult ages. Hence, because
our study primarily comprised individuals that were above
30 years of age (98.7%), current evidence suggest that the
FTO variant increases BMI in the ﬁrst 2 to 3 decades of life,
FIG. 2. Meta-analysis plot of the FTO-associated allele-wise effect on BMI using cross-sectional data. The results included in the meta-analysis are
from regression analysis adjusted for age, sex, and diabetes status. The weighting (%weight) represents the inverse variance of each study’s effect
estimator. A: Meta-analysis plot comprising all 41,504 individuals. No heterogeneity between the cohorts was detected (P = 0.242), and the overall
allelic effect was estimated to 0.28 kg/m2. B: Meta-analysis plot comprising all 41,504 individuals stratiﬁed on 10-year age strata. No heterogeneity
between the subgroups was detected (P = 0.378). Moderate heterogeneity was, however, observed in two of the subgroups.
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and from then on the BMI difference between the geno-
types becomes more or less constant throughout life. Nev-
ertheless, it remains to be seen whether other relevant
factors such as diet and physical activity may interact and
modify the susceptibility to obesity by the FTO variants
during the life course (37–39).
In summary, we have replicated that a common variant
in the FTO gene alters type 2 diabetes risk but ﬁnd that this
association is partly independent of the effect on BMI. Our
data further demonstrate that the weight gain as a result of
the FTO risk variant occurs during youth and that the BMI
difference according to the FTO genotype persists at the
same level throughout life, setting the threshold for BMI.
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Supplementary Table 1. Association results between the FTO SNP rs9939609 and obesity-related 
quantitative traits in 5,596 individuals from the HUNT2 cohort. 
 
Traits n Effect size* SE P-value† 
P-value 
SNP - age interaction‡ 
BMI 1985 (baseline) 4625 0.218 0.083 0.008 0.209 
BMI 1995 (follow-up) 5596 0.269 0.082 0.001 0.185 
 BMI 1985-95 4625 -0.019 0.051 0.716 0.889 
Waist-hip ratio 5552 0.003 0.001 0.023 0.968 
Waist circumference 5552 0.607 0.204 0.003 0.385 
Hip circumference 5553 0.417 0.163 0.010 0.204 
*All effect sizes represent the change in trait per risk allele. 
†Age, gender and diabetes status were included as covariates in the regression models. 
‡An additional SNP-age interaction term was introduced in the regression model to detect whether age 
modifies the associations. 
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Supplementary Figure 1. Scatter-plots showing the individual BMI values by age and FTO 
rs9939609 genotype for the HUNT2 subjects. The corresponding fitted curves are estimated by the 
locally weighted least squares method (LOWESS). Red, blue and green dots and smoothed curves 
represent those subjects homozygote for the risk allele, heterozygote and those without the risk 
allele, respectively. Note that the scatter-plots at the right are truncated and only contain BMI 
values between 20-35 kg/m2. The Lowess regression curves, however, are based on the whole range 
of BMI values (14.7 - 51.7 kg/m2) shown to the left. Panel A, B and C are scatter-plots with 
smoothed curves for BMI by age and genotype for all subjects combined, individuals without 
diabetes and for those with type 2 diabetes, respectively. 
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Supplementary Figure 2. Meta-analysis plots of association between FTO and type 2 diabetes, 
comprising 4,317 subjects with type 2 diabetes and 37,187 control subjects. Panel A: Meta-analysis 
plot of association between FTO rs9939609 and type 2 diabetes after correction for age and gender 
(allelic OR 1.13, 95% CI 1.08–1.19). Panel B: Meta-analysis plot of association between FTO 
rs9939609 and type 2 diabetes after correction for age, gender and waist-to-hip ratio (allelic OR 
1.12, 95% CI 1.07–1.17). Panel C: Meta-analysis plot of association between FTO rs9939609 and 
type 2 diabetes after correction for age, gender and waist circumference (allelic OR 1.11, 95% CI 
1.06–1.16). We observed a tendency towards heterogeneity between the samples (P = 0.04–0.09) in 
the meta-analyses, and the variation in the estimates attributable to heterogeneity was calculated 
to 63.7%, 58.2% and 69.3% for panel A, B and C, respectively. The ORs for the overall estimates 
were calculated using a fixed-effect model with inverse variance. The weighting (% weight) 
represents the inverse variance of each studies' effect estimator. 
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Supplementary Figure 3. Meta-analysis plots of association between FTO and risk to develop 
incident type 2 diabetes, comprising 3,143 subjects with incident type 2 diabetes during follow-up 
and 16,092 control subjects from the HUNT and MPP cohorts. Panel A: Meta-analysis plot of 
association between FTO rs9939609 and incident type 2 diabetes after correction for gender and 
baseline age (allelic OR 1.16, 95% CI 1.10-1.22, P=3.2×10-8). Panel B: Meta-analysis plot of 
association between FTO rs9939609 and type 2 diabetes after correction for gender and baseline 
age and BMI (allelic OR 1.12, 95% CI 1.05-1.18, P=1.1×10-4). Panel C: Meta-analysis plot of 
association between FTO rs9939609 and incident type 2 diabetes after correction for gender, 
baseline age and BMI and delta of BMI (allelic OR 1.11, 95% CI 1.05-1.18, P=1.5×10-4). The ORs 
for the overall estimates were calculated using a fixed-effect model with inverse variance. The 
weighting (% weight) represents the inverse variance of each studies' effect estimator.  
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